ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

ProQR Therapeutics N.V.NASDAQ: PRQR

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of €1.36M fell 69.9% year over year, behind the -36.4% change in trailing-twelve-month gross profit. Sequentially, it fell 65.7% from the prior quarter. Over 3 fiscal years it compounded at +52.2% a year.

Context

  • Gross profit amounted to 83.0% of revenue in FY2025, down 17.0 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -69.9% toward the trailing-twelve-month pace of -36.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.36M-65.7% QoQ
Last fiscal yearDec 2025
€12.68M-32.9% YoY
LTMMar 2026
€12.06M-36.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.9%——
1 year-32.9%——
3-year CAGR+52.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

EUR · from the income statement

Latest · FY2025
12.68M EUR
Year-over-year change
-32.9%
4-year CAGR
+75.6%

Gross Profit vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -36.4% is the 6th highest of 10, against a peer median of -4.9%.
  • Gross profit amounts to 89.7% of revenue for PRQR, versus a peer median of 99.1%.
PRQR Competitors
Gross Profit for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$201.36M USD+7.0%-4.1%92.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$41.35M USD-69.4%-32.2%91.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€12.06M EUR-36.4%+52.2%89.7%
EDITEditas Medicine, Inc.LTM Mar 2026$2.25M USD+105.3%+44.7%5.8%
ZURAZura Bio LimitedLTM Mar 2026-$16K USD-220.0%——
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$111K USD———
MREOMereo BioPharma Group plcLTM Mar 2026-$528.63K USD+51.3%+12.5%105.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$34.31M USD-119.9%—598.0%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$42.41M USD-4.9%——
IMMPImmutep LimitedFY2025-A$56.37M AUD-49.5%—1117.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M USD+23.8%——
Peer median (excluding PRQR) —-4.9%+4.2%99.1%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.